Trial · NCT01646021
Results by group63
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 63
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Ibrutinib | 15.6 | 95% Confidence Interval 10.6 to 25.1 | Months | |
| Progression Free Survival (PFS) | Temsirolimus | 6.2 | 95% Confidence Interval 4.2 to 7.8 | Months | |
| Overall Response Rate (ORR) | Ibrutinib | 77.0 | Percentage of participants | ||
| Overall Response Rate (ORR) | Temsirolimus | 46.8 | Percentage of participants | ||
| Overall Survival (OS) | Ibrutinib | 30.3 | 95% Confidence Interval 19.1 to 42.1 | Months | |
| Overall Survival (OS) | Temsirolimus | 23.5 | 95% Confidence Interval 13.0 to 30.7 | Months | |
| Duration of Response | Ibrutinib | 23.1 | 95% Confidence Interval 16.2 to 28.1 | Months | |
| Duration of Response | Temsirolimus | 6.3 | 95% Confidence Interval 4.7 to 8.6 | Months | |
| Time-to-Next Treatment | Ibrutinib | 31.8 | 95% Confidence Interval 23.3 to NA | Months | |
| Time-to-Next Treatment | Temsirolimus | 11.6 | 95% Confidence Interval 8.0 to 13.3 | Months | |
| Progression-Free Survival 2 | Ibrutinib | 26.2 | 95% Confidence Interval 17.2 to 32.4 | Months | |
| Progression-Free Survival 2 | Temsirolimus | 15.4 | 95% Confidence Interval 10.2 to 21.3 | Months | |
| Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym) | Ibrutinib | NA | 95% Confidence Interval 81.4 to NA | Weeks | |
| Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym) | Temsirolimus | 10.6 | 95% Confidence Interval 6.6 to 15.3 | Weeks | |
| Number of Participants Affected With Treatment-emergent Adverse Events | Ibrutinib | 139 | Participants | ||
| Number of Participants Affected With Treatment-emergent Adverse Events | Temsirolimus | 138 | Participants | ||
| Time to Response | Ibrutinib | 2.15 | Full Range 0.5 to 10.4 | Months | |
| Time to Response | Temsirolimus | 2.14 | Full Range 0.9 to 12.0 | Months | |
| Extent of Exposure of Time | Ibrutinib | 14.39 | Full Range 0.0 to 46.8 | Months | |
| Extent of Exposure of Time | Temsirolimus | 3.02 | Full Range 0.0 to 31.4 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01646021/results